Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)

Veronica Goffredo; Angelo Paradiso; Girolamo Ranieri; Cosmo Damiano Gadaleta

doi:10.1016/j.critrevonc.2011.01.012

Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)

Veronica Goffredo, Angelo Paradiso, Girolamo Ranieri, Cosmo Damiano Gadaleta

IRCCS Giovanni Paolo II

Research output: Contribution to journal › Article › peer-review

Abstract

The clinical application of the pure beta emitter ⁹⁰Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of ⁹⁰Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between ⁹⁰Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of ⁹⁰Y-therapies from the last decade and discusses new perspectives of therapeutic development.

Original language	English
Pages (from-to)	393-410
Number of pages	18
Journal	Critical Reviews in Oncology/Hematology
Volume	80
Issue number	3
DOIs	https://doi.org/10.1016/j.critrevonc.2011.01.012
Publication status	Published - Dec 2011

Keywords

Y-ibritumomab tiuxetan
DOTATOC
Microspheres
Neuroendocrine tumours
Non-Hodgkin's lymphoma
Radioembolization
Radionuclide therapy
Yttrium-90

ASJC Scopus subject areas

Oncology
Hematology
Geriatrics and Gerontology

Access to Document

10.1016/j.critrevonc.2011.01.012

Fingerprint Dive into the research topics of 'Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)'. Together they form a unique fingerprint.

Cite this

Goffredo, V., Paradiso, A., Ranieri, G., & Gadaleta, C. D. (2011). Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Critical Reviews in Oncology/Hematology, 80(3), 393-410. https://doi.org/10.1016/j.critrevonc.2011.01.012

Yttrium-90 (90Y) in the principal radionuclide therapies : An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). / Goffredo, Veronica; Paradiso, Angelo ; Ranieri, Girolamo ; Gadaleta, Cosmo Damiano.

In: Critical Reviews in Oncology/Hematology, Vol. 80, No. 3, 12.2011, p. 393-410.

Research output: Contribution to journal › Article › peer-review

Goffredo, V, Paradiso, A , Ranieri, G & Gadaleta, CD 2011, 'Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)', Critical Reviews in Oncology/Hematology, vol. 80, no. 3, pp. 393-410. https://doi.org/10.1016/j.critrevonc.2011.01.012

Goffredo V, Paradiso A , Ranieri G , Gadaleta CD. Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Critical Reviews in Oncology/Hematology. 2011 Dec;80(3):393-410. https://doi.org/10.1016/j.critrevonc.2011.01.012

Goffredo, Veronica ; Paradiso, Angelo ; Ranieri, Girolamo ; Gadaleta, Cosmo Damiano. / Yttrium-90 (90Y) in the principal radionuclide therapies : An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). In: Critical Reviews in Oncology/Hematology. 2011 ; Vol. 80, No. 3. pp. 393-410.

@article{1e63ab9c32114a0cb96bb0f58030362d,

title = "Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)",

abstract = "The clinical application of the pure beta emitter 90Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of 90Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between 90Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of 90Y-therapies from the last decade and discusses new perspectives of therapeutic development.",

keywords = "Y-ibritumomab tiuxetan, DOTATOC, Microspheres, Neuroendocrine tumours, Non-Hodgkin's lymphoma, Radioembolization, Radionuclide therapy, Yttrium-90",

author = "Veronica Goffredo and Angelo Paradiso and Girolamo Ranieri and Gadaleta, {Cosmo Damiano}",

year = "2011",

month = dec,

doi = "10.1016/j.critrevonc.2011.01.012",

language = "English",

volume = "80",

pages = "393--410",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Yttrium-90 (90Y) in the principal radionuclide therapies

T2 - An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)

AU - Goffredo, Veronica

AU - Paradiso, Angelo

AU - Ranieri, Girolamo

AU - Gadaleta, Cosmo Damiano

PY - 2011/12

Y1 - 2011/12

N2 - The clinical application of the pure beta emitter 90Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of 90Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between 90Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of 90Y-therapies from the last decade and discusses new perspectives of therapeutic development.

AB - The clinical application of the pure beta emitter 90Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of 90Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between 90Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of 90Y-therapies from the last decade and discusses new perspectives of therapeutic development.

KW - Y-ibritumomab tiuxetan

KW - DOTATOC

KW - Microspheres

KW - Neuroendocrine tumours

KW - Non-Hodgkin's lymphoma

KW - Radioembolization

KW - Radionuclide therapy

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=80655144474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80655144474&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.01.012

DO - 10.1016/j.critrevonc.2011.01.012

M3 - Article

C2 - 21388824

AN - SCOPUS:80655144474

VL - 80

SP - 393

EP - 410

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -